<DOC>
	<DOC>NCT00447681</DOC>
	<brief_summary>This a randomized, double-blind placebo-controlled inpatient/outpatient, sequential group study of ascending single IV doses of ILV-094, an investigational drug, administered to healthy subjects. In addition, there will be one sub-cutaneous dose cohort, which will follow the 25 mg IV dose.</brief_summary>
	<brief_title>Study of the Safety, Tolerability, Pharmacokinetics and Pharmcodynamics of ILV-094 in Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy subjects (Men or women of nonchildbearing potential ), aged 18 to 50 years. Body mass index in the range of 18 to 30 Kg/m2 and body weight greater than 50 Kg. Healthy as determined by the investigator on the basis of medical history, physical examination, clinical laboratory test results, vital signs, and 12lead electrocardiogram.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>